Henry Heine, Ph.D.
Institute for Therapeutic Innovation
6550 Sanger Road
Orlando, FL 32827
Research Microbiologist at USAMRIID for 11 years and continued at Ordway. Research has involved developing standardized methodology for establishment of susceptibility ranges of licensed and investigational antibiotics and efficacy aerosol-challenge animal models of infection for key strains of Biowarfare/Bioterrorism bacterial agents. At the request of the FDA the Clinical Laboratories Standards Institute (CLSI, formally, National Committee for Clinical Laboratory Standards, NCCLS) helped to establish and standardize this testing criteria for Biowarfare/Bioterrorism bacterial agents.
An important aspect and interest is the development and use of relevant animal models of infection for the BW/BT agents. Understanding the pathogenesis and disease history as it relates to human disease and using these models for advancement of therapies. The design of effective treatment regimens for antibiotic and other therapeutic interventions against any of the potential bacterial BW/BT agents present unique challenges. Most importantly, the traditional drug development paradigm is not applicable in this instance, given the (fortunate) paucity of naturally occurring human cases. Application of pharmacokinetic/pharmacodynamic (PK/PD) principles can assure that animal studies are designed in a manner that preserves their predictive value. Dr Heine has overseen numerous murine model efficacy trials and several non-human primate testing trials and regularly interacts with the FDA in the labeling of indications for antibiotics against the various BW/BT bacterial pathogens. Many of these studies have required application of GLP practices.
Additional interests include: bacterial physiology, applied immunology (immunomodulation therapies), pathogenesis, and Mycobacteriology.
Dr. Heine serves on the editorial board for the peer-reviewed journals Antimicrobial Agents and Chemotherapy and Applied and Environmental Microbiology. He is currently an active member of the American Society for Microbiology He served as a voting member and now as an advisor to the CLSI veterinary antimicrobial susceptibility testing committee (CLSI-VAST). While at USAMRIID he served on the “Public Health Emergency Medical Countermeasures Enterprise) (PHEMCE) which oversees advanced research, development, procurement, and stockpiling of medical countermeasures (e.g. vaccines, medicines, diagnostics, and other necessary medical supplies).
|Ph.D.||Uniform Services University||Microbiology|
|Post-Doctorial Training||Johns Hopkins University|
Member of University of Florida Select Agent Advisory Committee 2015 – present
Editorial Advisory Boards
Member of Applied and Environmental Microbiology Editorial Board, 2012-present.
Review approximately 18 submissions/year.
Member of Editorial Board Antimicrobial Agents and Chemotherapy, 2008-present,
Review approximately 25 submissions per year.
Reviewer for Scholarly Journals
Asked to complete 5-7 reviews per year for numerous journals including: Journal of Infectious Disease; PLOS one, Infection and Immunity, Journal Veterinary Research
Member Executive Committee, Consortium for Countermeasures for Weapons of Mass Destruction (CWMD). Term 2018-2021
Member of American Society of Microbiology 1983-present
Member of Clinical and Laboratory Standards Institute 2002-2013
Voting member on CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing 2006-2012
Advisor to CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing 2013-present
Most Outstanding Research Award, University of Florida Department of Florida
Arthur M. Friedlander, and Henry Heine. 2016. Antimicrobial Therapy and Vaccines Volume I: Microbes Third Edition. Bacillus anthracis (Anthrax). Apple Trees Productions, LLC. New York, New York. 67-72.
George L. Drusano, Henry Heine, and Arnold Louie. 2014. Fundamentals of Antimicrobials Pharmacokinetics and Pharmacodynamics. Clinical Pharmacodynamics of Quinolones. Springer. New York. 323-349.
Heine HS, Shadomy SV, Boyer AE, Chuvala L, Riggins R, Kesterson A, Myrick J, Craig J, Candela MG, Barr JR, Hendricks K, Bower WA, Walke H, Drusano GL. 2017. Evaluation of combination drug therapy for treatment of antibiotic-resistant inhalation anthrax in a murine model. Antimicrob Agents Chemother 61:e00788-17.
Heine HS, Miller L, Halasohoris S, Purcell BK. 2017. In vitro antibiotic susceptibilities of Francisella tularensis determined by broth microdilution following CLSI methods. Antimicrob Agents Chemother 61:e00612-17.
Grossman TH, Anderson MS, Drabek L, Gooldy M, Heine HS, Henning LN, Lin W,
Newman JV, Nevarez R, Siefkas-Patterson K, Radcliff AK, Sutcliffe JA. 2017. The Fluorocycline TP-271 is efficacious in models of aerosolized Bacillus anthracis infection in BALB/c mice and cynomolgus macaques. Antimicrob Agents Chemother 61:e01103-17.
Grossman TH, Anderson MS, Christ D,Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH,Sutcliffe JA. 2017. The fluorocycline TP-271 is efficacious in models of aerosolized Francisella tularensis SCHU S4 infection in BALB/c mice and cynomolgus macaques. Antimicrob Agents Chemother 61:e00448-17.
Heine, HS, Chuvala, L, Riggins, R, Cirz, R, Cass, R, Louie, A, and Drusano, GL. 2016. Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice. Antimicrobial Agents and Chemotherapy. 60(3): 1834-1840.
Heine, HS, Hershfield, J, Marchand, C, Miller, L, Halasohoris, S, Purcell, BK, and Worsham, P. 2015. In Vitro Antibiotic Susceptibilities of Yersinia pestis Determined by Broth Microdilution following CLSI Methods. Antimicrobial Agents and Chemotherapy. 59(4): 1919-1921.
Heine, HS, Louie A, Adamovicz, J, Amemiya, K, Fast, R, Miller, L, Opal, S, Palardy, J, Parajo, N, Sorgel, F, Kinzig-Schippers, M, and Drusano, GL. 2014. Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aersol in a Mouse Model of Pneumonic Plague. Antimicrobial Agents and Chemotherapy. 58(6): 3276-3284.
Heine HS, Chuvala L, Riggins R, Hurteau G, Cirz R, Cass R, Louie A, and Drusano GL(&). 2013. Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice. Antimicrob. Agents Chemother. 57(5): 2010-5.
Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, and Drusano GL. 2012. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob. Agents Chemother. 56(3): 1229-39.
Louie A, VanScoy BD, Heine HS 3rd, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, and Drusano GL. 2012. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 56(1): 513-7.
Louie A, Heine HS, VanScoy B, Eichas A, Files K, Brown DL, Liu W, Kinzig-Schippers M, Sorgel F, and Drusano GL. 2011. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimocrob. Agents Chemother. 55(2): 822-30.
H.S. Heine, S.V. Shadomy(&), A.E. Boyer(&), L. Chuvala(&), R. Riggins(&), J. Myrick(&), J. Craig(&), G.L.Drusano(&), M.G. Candela(&), J.R. Barr(&), K. Hensricks(&), W.A. Bower(&), and H. Walke(&). Poster. Evaluation of Synergistic Activities & Efficacy of Combination Drug Therapy for Antibiotic Resistant Inhalation Anthrax in a Murine Model. American Society for Microbiology Microbe. Boston, Massachusetts. Jun 16, 2016 – Jun 20, 2016.
H.S. Heine, S.T. Demons(&), L.L. Miller(&), S.A. Halasohoris(&), J. Myrick(&), L. Morris(&), and L. Chuvala(&). Poster. In vitro Activity of WCK771, a Broad Spectrum Anti-MRSA Benzoquinolizine subclass of Quinolone Against five Biodefense Bacterial Pathogens. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, California. Sep 17, 2015 – Sep 21, 2015.
HS. Heine, L. Chuvala(&), R. Riggins(&), J. Myrick(&), L. Morris(&), and G.D. Drusano(&). Poster. Application of Pharmacokinetics/Pharmacodynamics to Development of Fluoroquinolone Therapy to Treat Bacterial Biothreat Infections. American Society for Microbiology. New Orleans, Louisianna. Jun 1, 2015 – Jun 1, 2015.
H.S. Heine, L. Chuvala(&), R. Riggins(&), C. Jakielaszek(&), S. Novick(&), J. Hoover(&), and G. Feuerstein(&). Poster. Determination of the Ld50 and Ld90 for Aerosolized Francisella tularensis (FT) Schus4 in Mice and Identification of Factors to Control Aerosol Variability. ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC. Feb 9, 2015 – Feb 11, 2015.
S.A. Orr(&), D.K. O’Brien(&), J. C. Waldrep(&), M. L. Saylor(&), H. S. Heine, G. L. Drusano(&), R. L. DaSilva(&), N. J. Vietri(&), P. M. Silvera(&), and B. K. Purcell(&). Poster. A Pharmacokinetic Comparison of Intravenous Moxifloxacin in Cynomolgus Macaque and African Green Monkeys Using Monte Carlo Simulations to Support Animal Rule Efficacy Studies. ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC. Jan 27, 2014 – Jan 29, 2014.
H.S. Heine, L. Chuvala(&), R. Riggins(&), M. Gwynn(&), C. Jakielaszek(&), K. Widdowson(&), L. Miller(&), S. Halasohoris(&), J. Hershfield(&), and G. Feuerstein(&). Poster. In Vitro Activity and Efficacy in a Murine-Aerosol Challenge Model of a Novel Antibacterial GSK2140944 against Yersinia pestis. ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC. Jan 27, 2014 – Jan 29, 2014.
Marchand(&), H.S. Heine, L. Miller(&), S. Halasohoris(&), J. Hershﬁeld(&), A. Serio(&), and R. Cirz(&). Poster. In Vitro Activity of ACHN-975 Against Biodefense Pathogens. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver, Colorado. Sep 10, 2013 – Sep 13, 2013.
H.S. Heine, L. Chuvala, R.Riggins(&), and R. Cirz(&). Poster. Efﬁcacy of ACHN-975 in a Murine Pneumonic Plague (Yersinia pestis) Model. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver, Colorado. Sep 10, 2013 – Sep 13, 2013.